STOCK TITAN
  1. Home
  2. News
  3. HOLX

Hologic, Inc. - HOLX STOCK NEWS

Welcome to our dedicated news page for Hologic (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hologic's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hologic's position in the market.

News
Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography
Rhea-AI Summary
Bayer and Hologic Collaborate on Contrast-Enhanced Mammography Solution at Society of Breast Imaging Symposium, Aiming to Streamline Access and Education for Radiologists and Imaging Facilities
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
-
News
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024
Rhea-AI Summary
Hologic, Inc. (HOLX) will release its Q2 fiscal 2024 results on May 2, with a conference call at 4:30 p.m. ET. Interested parties can join via phone or webcast. Replay will be available on the company's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
earnings
-
News
Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
Rhea-AI Summary
Hologic, Inc. and Biotheranostics, Inc. announce study results showing 40% of patients with early-stage HR+ breast cancer had treatment recommendations changed based on the Breast Cancer Index test. The test helps identify women who may benefit from extended anti-estrogen therapy, avoiding both overtreatment and undertreatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
News
Hologic to Unveil Groundbreaking AI Research at ECR 2024
Rhea-AI Summary
Hologic, Inc. (Nasdaq: HOLX) presents new research in artificial intelligence (AI) at the annual European Congress of Radiology, showcasing the potential of deep-learning solutions in breast cancer detection. Dr. Sarah M. Friedewald will discuss the impact of Hologic's Genius AI® Detection solution on workflow efficiency and patient care. The company also highlights the superiority of its AI algorithm over traditional CAD algorithms, emphasizing innovation and collaboration with Bayer on contrast-enhanced mammography.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
AI
-
News
Hologic to Webcast Presentations at Upcoming Investor Conferences
Rhea-AI Summary
Hologic, Inc. (HOLX) to present at Raymond James' Institutional Investors Conference and Needham Virtual Healthcare Conference. Webcasts available for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
conferences
-
News
Hologic Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System
Rhea-AI Summary
Hologic, Inc. has received FDA clearance for its Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm, the first FDA-cleared digital cytology system that combines deep-learning-based artificial intelligence with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
none
News
Hologic Announces Financial Results for First Quarter of Fiscal 2024
Rhea-AI Summary
Hologic, Inc. (HOLX) reported revenue of $1,013.1 million, GAAP Diluted EPS of $1.03, and Non-GAAP Diluted EPS of $0.98, exceeding guidance. The company saw a 5.2% organic revenue growth excluding COVID-19, and delivered strong results in Breast Health and Surgical divisions. The financials for the first quarter of 2024 showed a decrease in revenue, primarily due to lower sales of COVID-19 assays compared to the prior year period. The company executed a $500 million accelerated share repurchase agreement (ASR), repurchased 2.2 million shares of its stock in open market trades for $150 million, and paid down $250 million of outstanding floating rate debt under its credit agreement. The company provided guidance for the second quarter and full year 2024, showing a strong outlook for fiscal 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
earnings
-
News
Women';s Health Remains in Crisis Worldwide Even as COVID-19 Pandemic Wanes
Rhea-AI Summary
The third annual Hologic Global Women’s Health Index reveals concerning trends in women's health, including billions of women untested for life-threatening conditions, worsening emotional health, and nearly 1 billion women living with physical pain. Taiwan tops the rankings of women’s health by country/territory, while the U.S. falls to number 30. Hologic, Inc. (Nasdaq: HOLX) partnered with Gallup to create the Index, which was launched at the World Economic Forum in Davos, Switzerland.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
covid-19
-
News
Hologic Launches ‘Better Is Possible’ Health Awareness Campaign for Women
Rhea-AI Summary
Company XYZ, a leading women's health company (Ticker: XYZ), urges women to openly discuss their health issues with their doctors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
News
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2024
Rhea-AI Summary
Hologic, Inc. (Nasdaq: HOLX) reported preliminary revenue results for its first fiscal quarter ended December 30, 2023, totaling approximately $1,013.1 million, exceeding the most recent revenue guidance range of $960 to $985 million. Despite a decrease compared to the prior year period, the company achieved 5.2% organic constant currency revenue growth, surpassing expectations. The company's Chairman, President, and CEO, Steve MacMillan, emphasized strong organic revenue performance, estimating over 9% growth in total company organic revenue excluding COVID-19. The preliminary results highlight divisional revenue changes, with Breast Health showing significant growth of 13.0% and GYN Surgical growing by 5.3%. Hologic expects non-GAAP diluted earnings per share (EPS) to be towards the high-end of the guidance range of $0.92 to $0.97 and plans to provide full financial results on February 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
earnings
Stock HOLX logo
Hologic, Inc.

Nasdaq:HOLX

HOLX Rankings

#552 Ranked by Market Cap
#2237 Ranked by Stock Gains
N/A Ranked by Dividends

HOLX Stock Data

18.15B
232.66M
0.75%
99.58%
1.89%
Irradiation Apparatus Manufacturing
Manufacturing
Link
US
Marlborough

About HOLX

driven by our ethos, the science of sure, we’re a diverse, dedicated, creative team that develops, markets and services some of the most innovative and accurate diagnostic imaging systems and surgical products on the planet. while we’re focused and passionate about our work, we never forget that what we’re really doing is giving people greater confidence and peace of mind in their diagnosis—enabling healthier lives, everywhere, every day. connect with us at hologic.com, on facebook at facebook.com/hologicjobs, and on twitter @hologic_jobs.